Stablecoin Development Corp
SDEV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SDEV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SDEV
Stablecoin Development Corp (SDEV) is a company that has divested its historical eyecare, wound care, and skin care businesses and is now pursuing a new strategic direction, which may include dissolution or another strategic alternative transaction.
Key risk: Negative shareholders' equity
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Stablecoin Development Corp (SDEV) is a company that has divested its historical eyecare, wound care, and skin care businesses and is now pursuing a new strategic direction, which may include dissolution or another strategic alternative transaction.
- The company has undergone significant changes, including the Avenova Asset Divestiture in January 2025, selling its primary eyecare business [sec_mda · as of 2025-08-14].
- As of June 30, 2026, the company reported cash & equivalents of $7.1M, total revenue of $2.2M, net income of -$41.1M, and shareholders' equity of -$631.8M [sec].
- Management believes existing cash will be sufficient to meet planned operating expenses at least through November 7, 2026, based on funds available as of September 30, 2025 and proceeds from Series E Preferred Stock and warrants [sec_mda · as of 2025-11-07].
- The company is pursuing a new direction that may result in dissolution or another strategic alternative transaction [sec_mda · as of 2025-04-02].
- The company has faced NYSE American listing compliance issues, including regaining compliance with minimum stockholders' equity requirements [sec_mda · as of 2025-11-07].
What works
- Management believes existing cash and cash equivalents will be sufficient to meet planned operating expenses at least through November 7, 2026 [sec_mda · as of 2025-11-07].
- The company has regained compliance with NYSE American minimum stockholders' equity requirements [sec_mda · as of 2025-11-07].
What to weigh
- The company has a significant accumulated deficit, with shareholders' equity of -$631.8M as of June 30, 2026 [sec].
- The company has divested its primary operating businesses and is now pursuing dissolution or another strategic alternative, indicating a lack of ongoing core operations [sec_mda · as of 2025-08-14].
- The company faces risks of delisting from NYSE American if it does not maintain compliance [sec_mda · as of 2025-08-14].
From the filings
Quoted directly from source documents.
The company sold its primary eyecare business in January 2025.
“The Avenova Asset Divestiture which closed on January 17, 2025 and in which we sold our primary eyecare business”
SEC MD&A · August 14, 2025
The company is considering dissolution or another strategic alternative.
“we are pursuing a new direction that may result in the Dissolution of our Company or another strategic alternative transaction”
SEC MD&A · April 2, 2025
Cash runway is expected through at least November 7, 2026.
“management believes that the Company's existing cash and cash equivalents will be sufficient to enable the Company to meet its planned operating expenses at least through November 7, 2026”
SEC MD&A · November 7, 2025
Risks & what to watch (3)›
Key risks
- Negative shareholders' equity — Shareholders' equity is -$631.8M as of June 30, 2026, indicating a substantial deficit [sec].
- Uncertain strategic direction
- NYSE American delisting risk — The company may face delisting if it fails to maintain compliance with exchange requirements [sec_mda · as of 2025-08-14].
What to watch
- Any announcement regarding the company's strategic direction, including potential dissolution or alternative transaction [sec_mda · as of 2025-04-02].
- Updates on NYSE American listing status and compliance [sec_mda · as of 2025-11-07].
- Cash burn rate and whether the company will need additional financing before November 2026 [sec_mda · as of 2025-11-07].
Sources: News · SEC filings · SEC MD&A · Generated August 19, 2026 · How we verify sources →
Run Stablecoin Development Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Stablecoin Development Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
3.7 months
D/E 0.00 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Short Interest
as of May 21, 2026- % of float
- 9.8%
- Days to cover
- 0.7
- Shares short
- 333,120
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SDEV short interestFrequently asked questions
What is the AI investment thesis for Stablecoin Development Corp?
Stablecoin Development Corp (SDEV) is a company that has divested its historical eyecare, wound care, and skin care businesses and is now pursuing a new strategic direction, which may include dissolution or another strategic alternative transaction.
Who is the CEO of Stablecoin Development Corp?
Mr. Michael John Kazley is the chief executive officer of Stablecoin Development Corp (SDEV).
Where is Stablecoin Development Corp headquartered?
Stablecoin Development Corp (SDEV) is headquartered in EmeryVille, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.